Invokana® (Canagliflozin)

Invokana (Canagliflozin) is a sodium glucose co-transporter 2 inhibitor (SGLT2i) indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.1  In the recently published ADA/EASD Guidelines*, SGLT2i are recommended as a second line oral agent for treating T2DM patients with;2

  • Predominant established atherosclerotic cardiovascular disease
  • Predominant heart failure or chronic kidney disease
  • A compelling need to minimise hypoglycaemia
  • A compelling need to minimise weight gain or promote weight loss

 

References
  1. Invokana SmPC, www.medicines.ie
  2. Davies, M.J., D’Alessio, D.A., Fradkin, J et al. Diabetologia (2018) 61:2461. https://doi.org/10.1007/s00125-018-4729-5
    * American Diabetes Association and European Society for the Study of Diabete
    s